The immune landscape of prostate cancer and nomination of PD-L2 as a potential therapeutic target

SG Zhao, J Lehrer, SL Chang, R Das… - JNCI: Journal of the …, 2019 - academic.oup.com
Background Immunotherapy has been less successful in treating prostate cancer than other
solid tumors. We sought to better understand the immune landscape in prostate cancer and …
被引用次数：166 相关文章

The immune landscape of prostate cancer and nomination of PD-L2 as a potential therapeutic target

SG Zhao, J Lehrer, SL Chang… - Journal of the …, 2019 - mayoclinic.elsevierpure.com
Background: Immunotherapy has been less successful in treating prostate cancer than other
solid tumors. We sought to better understand the immune landscape in prostate cancer and …

The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target

SG Zhao, J Lehrer, SL Chang, R Das… - Journal of the …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Immunotherapy has been less successful in treating prostate cancer than other
solid tumors. We sought to better understand the immune landscape in prostate cancer and …

The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.

SG Zhao, J Lehrer, SL Chang, R Das… - Journal of the …, 2019 - europepmc.org
Background Immunotherapy has been less successful in treating prostate cancer than other
solid tumors. We sought to better understand the immune landscape in prostate cancer and …

The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target

SG Zhao, J Lehrer, SL Chang, R Das… - JNCI: Journal of the …, 2019 - academic.oup.com
Background Immunotherapy has been less successful in treating prostate cancer than other
solid tumors. We sought to better understand the immune landscape in prostate cancer and …

The immune landscape of prostate cancer and nomination of PD-L2 as a potential therapeutic target

SG Zhao, J Lehrer, SL Chang… - Journal of the …, 2019 - scholars.northwestern.edu
Background: Immunotherapy has been less successful in treating prostate cancer than other
solid tumors. We sought to better understand the immune landscape in prostate cancer and …